title: Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.
abstract: A strain of human cytomegalovirus, T2211, modified from standard laboratory strain AD169 to contain a secreted alkaline phosphatase reporter gene for rapid viral quantitation, was cloned as a bacterial artificial chromosome, BA1, and then mutagenized to create recombinant viruses containing viral UL97 kinase sequence variants found in clinical specimens after ganciclovir treatment, but with no phenotypic data to determine their role in drug resistance. Seven control strains and 14 other recombinant strains were phenotyped for ganciclovir resistance and compared with similar strains created using prior technology to show a good concordance of findings. Sequence changes V466M, H469Y, A478V, N510S, A588V, K599R, L600I, G623S, T659I, and V665I were found to confer no significant ganciclovir resistance, while mutations L405P, M460T, A594E, and C603R conferred 3- to 9-fold increases in ganciclovir 50% inhibitory concentrations. Different mutations at codons 594 (A594V, A594E) and 603 (C603W, C603S) conferred varied amounts of ganciclovir resistance. Advances in recombinant phenotyping make it easier to show that many uncharacterized UL97 sequence variants do not confer ganciclovir resistance, but some are newly confirmed as resistance associated, including one (L405P) which is outside the codon range where such mutations are usually found. This information should improve the interpretation of genotypic data generated by diagnostic laboratories.
authors.affiliation: Division of Infectious Diseases, Oregon Health and Science University, and Department of Veterans Affairs Medical Center, Portland, Oregon, USA. chous@ohsu.edu
authors.forename: Sunwen
authors.initials: S
authors.lastname: Chou
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D001483:Base Sequence; D022202:Chromosomes, Artificial, Bacterial / Q000235:genetics; D003001:Cloning, Molecular; D003587:Cytomegalovirus / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics*; D017931:DNA Primers / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics; D015774:Ganciclovir / Q000494:pharmacology*; D005814:Genes, Viral; D014644:Genetic Variation; D006801:Humans; D066298:In Vitro Techniques; D016296:Mutagenesis; D010641:Phenotype; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics*; D011995:Recombination, Genetic
chemical_list: D000998:Antiviral Agents; D017931:DNA Primers; D017853:Phosphotransferases (Alcohol Group Acceptor); C075365:ganciclovir kinase; D015774:Ganciclovir
references.citation: Drug Resist Updat. 2002 Apr;5(2):88-114
references.pmid: 12135584
references.citation: Lancet. 2000 Aug 19;356(9230):645-9
references.pmid: 10968438
references.citation: Science. 1988 Jul 1;241(4861):42-52
references.pmid: 3291115
references.citation: J Infect Dis. 2001 Dec 15;184(12):1598-602
references.pmid: 11740736
references.citation: J Virol. 1999 Oct;73(10):8320-9
references.pmid: 10482582
references.citation: Antiviral Res. 2002 Apr;54(1):59-67
references.pmid: 11888658
references.citation: J Clin Invest. 1995 Jan;95(1):257-63
references.pmid: 7814623
references.citation: J Infect Dis. 1997 Sep;176(3):786-9
references.pmid: 9291334
references.citation: J Infect Dis. 2001 Jan 15;183(2):333-337
references.pmid: 11120934
references.citation: J Clin Virol. 2010 Apr;47(4):321-4
references.pmid: 20138805
references.citation: Nucleic Acids Res. 2005 Feb 24;33(4):e36
references.pmid: 15731329
references.citation: Antiviral Res. 1998 Dec;40(1-2):95-103
references.pmid: 9864050
references.citation: J Virol. 1998 Jul;72(7):5927-36
references.pmid: 9621055
references.citation: Am J Transplant. 2005 Jun;5(6):1462-8
references.pmid: 15888055
references.citation: J Infect Dis. 2007 Jul 1;196(1):91-4
references.pmid: 17538888
references.citation: Rev Med Virol. 2008 Jul-Aug;18(4):233-46
references.pmid: 18383425
references.citation: J Heart Lung Transplant. 2007 Dec;26(12):1286-92
references.pmid: 18096480
references.citation: Antimicrob Agents Chemother. 2005 Jul;49(7):2710-5
references.pmid: 15980340
references.citation: J Infect Dis. 2002 Jan 15;185(2):162-9
references.pmid: 11807689
references.citation: J Infect Dis. 2002 Sep 15;186(6):760-8
references.pmid: 12198609
references.citation: J Gen Virol. 1998 Sep;79 ( Pt 9):2105-12
references.pmid: 9747718
references.citation: J Infect Dis. 1998 Aug;178(2):531-4
references.pmid: 9697737
references.citation: J Mol Biol. 1967 Jun 14;26(2):365-9
references.pmid: 4291934
references.citation: J Infect Dis. 1995 Mar;171(3):576-83
references.pmid: 7876604
references.citation: Clin Infect Dis. 1995 Oct;21 Suppl 2:S170-3
references.pmid: 8845447
references.citation: J Clin Virol. 2008 Sep;43(1):107-9
references.pmid: 18502683
references.citation: J Infect Dis. 2006 Sep 1;194(5):579-83
references.pmid: 16897654
references.citation: J Med Virol. 2009 Mar;81(3):507-10
references.pmid: 19152402
references.citation: Antimicrob Agents Chemother. 2001 Oct;45(10):2775-80
references.pmid: 11557468
references.citation: J Virol. 1994 Jul;68(7):4427-31
references.pmid: 8207815
references.citation: J Infect Dis. 1997 Jul;176(1):69-77
references.pmid: 9207351
references.citation: Rev Med Virol. 2009 Jul;19(4):215-29
references.pmid: 19434630
references.citation: Antimicrob Agents Chemother. 2005 Mar;49(3):873-83
references.pmid: 15728878
references.citation: J Clin Microbiol. 2007 Aug;45(8):2681-3
references.pmid: 17537934
references.citation: J Clin Virol. 1999 Aug;13(3):141-8
references.pmid: 10443790